London‑based Global Healthcare Opportunities (GHO) and Singapore’s CBC Group are negotiating a new global fund following their merger. The combined entity, which will control more than $21 billion in assets, aims to channel capital into Asia’s fast‑growing life‑science ecosystem. Investors see China’s biotech surge and the region’s expanding clinical‑trial capacity as a catalyst for cross‑border deals.

The merger pairs CBC’s deep experience in Asia‑Pacific with GHO’s foothold in Europe and North America, creating a platform that can arbitrage supply chains and R&D across continents. Mike Mortimer, GHO managing partner, said the joint venture will help American and European life‑science service providers connect with Asian customers and Chinese, Korean drugmakers seeking global market access.

Western pharma giants such as Pfizer, GSK and AstraZeneca have already signed multi‑billion‑dollar agreements to license Chinese cancer and obesity candidates. By pooling resources, CBC Group and GHO intend to capture a share of those pipelines and facilitate equipment sales to Asian manufacturers. The new fund therefore sharpens investors’ exposure to the region’s rising valuation and supply‑chain leverage.

For capital allocators, the combined platform offers a single point of contact to invest in Asia‑centric biotech ventures and related infrastructure. With a unified AUM base exceeding $21 billion, the fund can underwrite sizeable rounds and negotiate preferential terms, potentially reshaping the financing landscape for Chinese start‑ups and accelerating cross‑border M&A activity.